Simplr has originated the opportunity to introduce private sector investment to this potentially life-changing, cutting-edge cancer treatment, regenerative medicine, and disease prevention technology in Bali. Simplr Health also has clinical and advisory support from Prof Linfa Wang, Professor, Emerging Infectious Diseases Duke-NUS Medical School; Prof Peter Everts, CSO, EmCyte Corp Program Director, Gulf Coast Biologics; Fellow Royal Society of Medicine, London and others. See www.simplr.group for more information.

Founded in 2010, this Japanese commercial laboratory provides regenerative cell medicine based on advanced and highly safe culture technology.

Professor Hiroshi Kawamoto MD PhD has agreed to support Simplr in an advisory capacity. Prof Hiroshi is Head of Immunology, Department of Regenerative Science and Director of the Institute for Life and Medical Science, Kyoto University.

SingMedic is local partner and medical tourism management provider. SingMedic represents hospitals in Singapore, Malaysia, Thailand and South Korea. They provide clients with detailed information and recommendations about medical and aesthetic treatments, including help with appointments. The company was founded in 2007 and has helped more than 40,000 Indonesians getting medical treatment overseas.

Seta Clinic Group is the proposed Operator and Manager of the Facility. Established in 1999 in Tokyo, Japan, the Seta Clinic Group is a pioneer in Immuno-Cell Therapy for cancer patients and is Japan's longest running ICT treatment facility. With over 13,000 patients treated, they have led significant advancements in this non-invasive, quality-of-life-enhancing treatment.